Bacteriophage therapy for bacterial disease in fish and shrimp farming instead of medicated-feed antibiotics
Antibiotics in medicated feed and bath treatments - oxytetracycline, florfenicol, oxolinic acid, enrofloxacin, sulfonamide-trimethoprim (complementing F01 vaccination for the diseases no vaccine covers)
Suppliers 3
| Aristogene Biosciences Pvt. Ltd. | India | active |
| PhageLab | Chile | active |
| Intralytix | United States | active |
Route into Russia / EAEU VET
- Regulator
- Rosselkhoznadzor
- Typical time
- 155-235 working days under EAEU rules (plus dossier); national 61-FZ route open until 31.12.2027
- Legal basis
- EEC Council Decision No. 1 (21.01.2022), EAEU rules for veterinary medicines; Federal Law 61-FZ (national procedure until 2027)
Information, not legal advice — confirm the procedure for your product.
Proof 4 claims
Conventional antibiotic treatment (e.g., oxytetracycline, florfenicol, quinolones) mixed into feed.
Bacteriophage therapy (phage cocktails or monophage preparations) administered via feed, immersion, or injection.
- Displaced at scale?
- no
- Caveats
- There is no evidence of bacteriophage therapy displacing conventional antibiotic use at a commercial scale. Current applications are limited to research, laboratory-scale trials, or small-scale pilot studies. No national or global time-series data exists showing a reduction in antibiotic volume due to phage adoption.
- Market
- Alternative: [2980 2980]; Incumbent: ; Status: partial;
- checked
- 2026-10-06
| Bacteriophage therapy has not displaced conventional antibiotic use at scale in commercial aquaculture. · 2026 · pilot or niche | peer-reviewed www.sciencedirect.com |
| In controlled trials, phage therapy has demonstrated survival rates comparable to or higher than those achieved with conventional antibiotics. “Notably, a previous study showed that the use of phage cocktails in shrimp infected with pathogenic Vibrio sp. resulted in a 91.4% survival rate, a comparable outcome to that of antibiotic treatments at 91.6%.” · 2020-2024 · | peer-reviewed www.nature.com |
| A small-scale study in India indicated that phage-based formulations could be more economical than probiotics. “The results suggest that the use of a bacteriophage-based formulation against vibrios resulted in better growth, survival, FCR and production of Litopenaeus vannamei. The benefit-cost ratio was also higher in the bacteriophage treated ponds.” · 2020 · | weak (company, news, market research, other) thefishsite.com |
| The primary drivers for researching phage therapy are the rise of antimicrobial resistance (AMR) and strict regulatory guidelines regarding antibiotic residues in aquaculture products. “The use of antibiotics in combating infections is a breakthrough for aquaculture in the past, but the rising antibiotic resistance is posing an immense threat to their livelihood due to strict regulatory guidelines.” · 2021-2025 · | peer-reviewed www.sciencedirect.com |
Details
Replaces: medicated-feed antibiotics for bacterial disease · Species: fish and shrimp · Evidence: medium
The chemical problem#
Bacterial disease is the main reason antibiotics enter aquaculture. Furunculosis and enteric redmouth (Aeromonas salmonicida, Yersinia ruckeri), vibriosis (Vibrio anguillarum, V. harveyi), motile Aeromonas septicaemia in tilapia and catfish, Edwardsiella infections - these are treated by mixing oxytetracycline, florfenicol or quinolones into feed for whole ponds, or by bath treatments. A large share of the dose never reaches the fish: it dissolves into water and sediment, where resistance genes can move into environmental and human pathogens. Quinolones and third-generation cephalosporins used in fish farming overlap with critically important human antibiotics, and importing markets increasingly test for residues.
Product overview#
Bacteriophages are viruses that infect and lyse bacteria, and only bacteria - they cannot touch fish, shrimp, plants or people. Phage therapy isolates lytic phages that match the bacterial strain causing an outbreak (from farm water, effluents or the infected fish itself), amplifies them in the lab, and returns them to the farm as a tailored product - a suspension for immersion baths, a feed top-coating, or an injection for broodstock. Because each phage typically attacks one (or a few) bacterial strains, products are built as cocktails of 3-10 phages to cover the local pathogen diversity.
For aquaculture this is a natural fit: the water environment makes immersion and in-feed delivery easy, the target bacteria sit on skin, gills and gut surfaces where phages accumulate, phages replicate at the infection site (the dose grows exactly where it is needed), and they wash out and decay when the target is gone - no residue, no withdrawal period. The approach fills the space where no vaccine exists yet (see F01 for the vaccine backbone) and where antibiotics are the only current tool, and it complements F04’s biofloc-and-probiotics management.
Active ingredient / Composition#
Purified suspensions of lytic bacteriophages (typically 10^6-10^9 PFU/mL), formulated singly or as multi-phage cocktails matched to the farm’s outbreak strain; stored cool (2-8 C) and applied within days of production for tailored products. Freeze-dried formulations for feed coating are in development. Non-target bacteria and the host animal’s cells are unaffected.
Key facts#
| Parameter | Value |
|---|---|
| Class | Bacteriophages (bacterial viruses; biological control agent) |
| Spectrum | Pathogen-strain specific; cocktails broaden coverage |
| Routes | Immersion/bath, in-feed top-coating, injection (broodstock) |
| Dose (trials) | 10^6-10^9 PFU per mL of bath or per gram of feed |
| Residues / withdrawal | None known; phages are proteins and nucleic acids that decay in the environment |
| Regulatory | Not yet authorized as veterinary medicinal products in most jurisdictions - pilot/compassionate frameworks; check national rules before use |
Advantages#
- Species-specific: spares the gut microbiome, pond microbiota and non-target bacteria - unlike broad-spectrum antibiotics.
- Self-amplifying: a small dose grows at the infection site as long as target bacteria are present; stops when they are gone.
- Works against antibiotic-resistant bacteria: phages kill by a mechanism to which bacteria have no cross-resistance with antibiotics; used where antibiotic therapy is failing.
- No residues, no withdrawal: a direct fit for export markets testing for antibiotic residues; safe for the operator.
- Tailored per farm: a local production model (isolate today’s strain, deploy next week) suits regional hatcheries and integrated farms.
Mode of action#
A lytic phage attaches to specific surface receptors on its host bacterium, injects its genome, replicates inside, and bursts the cell (lysis), releasing 50-200 new phages that attack neighbouring cells of the same strain. In a cocktail, phages with different receptors lower the chance of resistance; efficacy is amplified by the local concentrations at skin, gill and gut surfaces after immersion or feeding.
Application#
| User | Target | Method, timing and specifics |
|---|---|---|
| Hatchery | Vibrio, Aeromonas in larvae and juveniles | Immersion baths at 10^6-10^7 PFU/mL for 1-6 h; repeat per production cycle |
| Grow-out farm (finfish) | Furunculosis, enteric redmouth, motile Aeromonas | Feed top-coating or immersion at first outbreak signs; match phages to the isolated strain |
| Shrimp ponds | Luminous vibriosis, AHPND-related Vibrio | Immersion/pond-dosing of tailored cocktails; combine with water-quality management (F04) |
| Broodstock | Vertical transmission control | Injection or immersion before spawning |
| Diagnostic-first strategy | All | Culture the pathogen, build/select the matching cocktail, then treat - phages are a targeted tool, not a blanket one |
Limitations#
- Narrow host range: a product for one farm’s strain may miss another farm’s; requires diagnostics and local production or exchange networks.
- Bacteria can acquire resistance to a single phage; cocktails, rotation and dosing matter - the same discipline as antibiotic stewardship, adapted.
- Delivery and stability: phages are sensitive to UV, heat, extreme pH and some disinfectants; feed coating and cold-chain costs matter.
- Regulatory gap: no ordinary authorization pathway yet for most markets (veterinary medicines frameworks are adapting); commercial products are few, so pilots need legal groundwork.
- Field evidence is still thinner than for vaccines: trials dominate over multi-season commercial programmes.
Evidence of displacement — D0: no verified evidence#
No verified figure was found for this substitution.
Suppliers - real products and services (from the vendor index)#
Companies below are active vendors in the vendor index whose own card (profile / official website) shows this product or service · matched 2026-09-29 by keyword and checked by hand against the card text. Being listed is not an endorsement; open each card for evidence, contacts and status.
| Company | Region · Country | What the index shows | Card |
|---|---|---|---|
| Aristogene Biosciences Pvt. Ltd. | Asia · India | commercial phage products for poultry and aquaculture infections | card |
| PhageLab | LatAm · Chile | tailor-made bacteriophage solutions for animal production (livestock and poultry) | card |
| Intralytix | NA · United States | bacteriophage products for food safety and veterinary uses | card |
Government funding signals#
Scanned 2026-09-29 (OpenAIRE projects + US NSF keyword search); candidates reviewed by hand.
Signal: Weak. 1 relevant project located - Portugal, FCT PTDC/AAC-AMB/112934/2009, “Phage therapy as a low environmental impact alternative to inactive pathogenic bacteria in aquaculture” (2011, EUR 22,500). The sector is currently company- and university-led rather than grant-led; France and Chile host most commercial activity. Honest limitation: the scan covers OpenAIRE + US NSF only.
Scientific evidence#
- Nakai T, Park SC (2002). Bacteriophage therapy of infectious diseases in aquaculture. Research in Microbiology 153: 13-18.
- Richards GP (2014). Bacteriophage remediation of bacterial pathogens in aquaculture: a review of the technology. Bacteriophage 4: e975540.
- Sillankorva SM, Oliveira H, Azeredo J (2012). Bacteriophages and their role in food safety. International Journal of Microbiology 2012: 863945.
- Doss J, Culbertson K, Hahn D, Camacho J, Barekzi N (2017). A review of phage therapy against bacterial pathogens of aquatic and terrestrial organisms. Viruses 9: 50.
Bioeconomy value#
Phage therapy turns aquaculture health away from a shared global resource - the antibiotic pipeline - and toward a locally produced biological tool: medicine that is multiplied where it is needed, from the farm’s own pathogens. It is one more pillar of the shift from blanket chemistry to diagnosis-plus-targeted-biology (see F01, F04), with a clean export story: no residues, no withdrawal, no resistance pressure on human-critical antibiotics.
Part of the fishery programme: F01 vaccination backbone, F04 biofloc/probiotics management, F05 parasite control.